Active Ingredient History
Azoximer bromide, sold by the trade name Polyoxidonium by Petrovax NPO, is a water-soluble cationic polymer, adjuvant for use with the hemagglutinin glycoprotein-based influenza vaccine Grippol. Azoximer bromide is a ternary copolymer of 1,4-ethylene piperazine, 1,4-ethylene piperazine-N-oxide, and (N-carboxymethylene)-1,4-ethylene piperazinium bromide with a molecular weight of 60–100 kDa. A derivative of poly(1,4-ethylene piperazine), it is synthesized by a partial oxidation of the parent polymer with hydrogen peroxide to introduce N-oxide groups followed by the quaternization of non-oxidized amino groups with bromoacetic acid. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Asthma (Phase 4)
Coronavirus Infections (Phase 2/Phase 3)
Pneumococcal Infections (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Respiratory Tract Infections (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue